Physician profile
Upinder Singh
NPI 1609846229
$7,312.71
in general payments reported to CMS, 2019-2025
10 companies · $499 in 2025
The $499 reported for 2025 was more than what 79% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2023: $1,227 · 2024: $5,131 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,565 · Food and Beverage: $1,569 · Consulting Fee: $1,085 · Travel and Lodging: $637.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,565.00 |
| Food and Beverage | $1,569.25 |
| Consulting Fee | $1,085.00 |
| Travel and Lodging | $637.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $5,804.70 | 2023-2025 | |
| Cipla USA INC. | $456.14 | 2021 | |
| Abbvie INC. | $259.55 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $253.20 | 2024-2025 | Breztri |
| Penumbra, INC. | $147.90 | 2025 | Indigo System |
| Bayer Healthcare Pharmaceuticals INC. | $121.83 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $107.59 | 2023 | Seglentis |
| Advanced Medical Administration | $70.60 | 2025 | Amniograft |
| Livanova USA, INC. | $67.36 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Sanofi-Aventis U.S. LLC | $23.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.